Treatment options for metastatic hormone-sensitive prostate cancer
Mené sur 654 patients atteints d'un cancer de la prostate hormonosensible, de haut volume et de stade métastatique (durée médiane de suivi : 21,2 mois), cet essai de phase III compare l'efficacité, du point de vue de la survie sans progression et de la survie globale, et la toxicité du rezvilutamide et du bicalutamide, dispensés en combinaison avec une thérapie anti-androgénique
The treatment landscape for metastatic, hormone-sensitive prostate cancer has transformed in recent years, with the emphasis now on early treatment intensification through a combination approach to systemic therapy. Now that the addition of a second-generation anti-androgen or docetaxel is known to confer a survival benefit, androgen deprivation therapy (ADT) monotherapy is no longer considered sufficient. In fact, for selected patients with de novo, high-volume, metastatic, hormone-sensitive prostate cancer, triplet therapy with ADT, an androgen-receptor inhibitor, and docetaxel is most efficacious. Despite compelling data to support a combination approach, however, uptake in the real world remains disappointingly low, with many patients still receiving ADT alone.
The Lancet Oncology , commentaire, 2021